Search

Palbociclib

[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

Givinostat

[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).

Linerixibat

[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

Gepotidacin

[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

Sodium phosphate, dibasic, unspecified form

Iopodic acid

This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

Cabazitaxel

[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].

Lutetium Lu-177 vipivotide tetraxetan

[L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

Respiratory syncytial virus vaccine, adjuvanted

[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]

Zinc oxide

Zinc oxide is an inorganic compound used in a number of manufacturing processes. It can be found in rubbers, plastics, ceramics, glass, cement, lubricants, paints, ointments, adhesives, sealants, pigments, foods, batteries, ferrites, fir...